Your session is about to expire
← Back to Search
Everolimus + Letrozole for Ovarian Cancer
Study Summary
This trial is testing if the combination of everolimus (Afinitor®) and letrozole is effective in the treatment of women with either recurrent or persistent epithelial ovarian, fallopian tube, primary peritoneal or endometrial cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: Single
Frequently Asked Questions
Is the age criterion for this experiment restricted to those over 45?
"In accordance with the study's enrollment guidelines, participants must be at least 18 years old and no older than 80."
Are there any additional investigations into the combined effects of everolimus and letrozole?
"Currently, 241 everolimus and letrozole studies are ongoing worldwide. Of those trials, 54 have entered Phase 3 of the clinical trial process. Amongst these sites, Shanghai has the highest concentration with 13459 locations dedicated to studying this particular treatment."
What are the prerequisites for participating in this clinical trial?
"The current aim of this clinical trial is to enrol 20 participants suffering from carcinoma, ovarian epithelial aged between 18 and 80. To qualify for the study, applicants must exhibit the following prerequisites: a diagnosis of relapse or refractory/persistent epithelial ovarian, fallopian tube or primary peritoneal carcinomia; evidence via pathology report that they have received treatment with a platinum-based chemotherapy regiment containing carboplatin and cisplatin; postmenopausal/post oophorectomy status; an ECOG performance score less than 2; may but are not required to have already had one additional cytotoxic regimen"
What potential risks does the combination of everolimus and letrozole pose to individuals?
"The safety of everolimus and letrozole have been judged to be a 2 on the 1-3 scale. This is due to evidence showing its security, however no data has proven it effectiveness in Phase 2 trials."
What maladies are typically managed with a combination of everolimus and letrozole?
"Everolimus and letrozole are often prescribed to address liver transplant rejection, yet they can also be employed in the treatment of kidney transplants, Waldenstrom macroglobulinemia, and tamoxifen."
Is the recruitment process for this study still open?
"Clinicialtrials.gov confirms that this trial, first posted on June 1st 2014 and revised May 18th 2015, is not actively seeking enrolment at present. However, there are 2,055 other studies with open recruitment presently available to potential patients."
What is the aggregate number of participants enrolled in this experiment?
"This clinical trial is no longer accepting new participants as it was last updated on May 18th, 2015. However, if you are searching for alternative studies there are currently 1,814 trials enrolling patients with carcinoma ovarian epithelial and 241 ongoing everolimus/letrozole examinations seeking volunteers."
Share this study with friends
Copy Link
Messenger